Pfizer replaced Merck as the pharmaceutical company most respected by physicians, according to Scott-Levin.
Pfizer replaced Merck as the pharmaceutical company most respected by physicians, according to a new strategic study by Scott-Levin, Newtown, PA.
Good research and development, credibility, educational orientation, sensitivity to pricing concerns and orientation to patient information were strengths that physicians judged superior in Pfizer.
"Firms with a strong research and development reputation tend to perform better in overall company rankings," noted Joy Scott, CEO of Scott-Levin. "Pfizer's high position can also be attributed to strong sales and marketing and innovative new products."
Recent drug launches, such as Viagra, Lipitor and Aricept, boosted Pfizer's ranking, according to Scott-Levin.
Pfizer was ranked first by nurse practitioners, physician assistants and HMO medical directors as well. However, pharmacists, pharmacy drug chain executives, drug wholesalers, hospital buying groups and nursing home pharmacy consultants rated Merck as the most respected company. Novartis was voted most respected by pharmacy benefit management executives and HMO pharmacy directors.
Broken down among physician specialty groups, other pharmaceutical companies fared slightly better. Although general practitioners and internists stood by Pfizer, OB/GYNs rated Johnson & Johnson most respected, pediatricians cast their votes for Abbott Laboratories and psychiatrists gave the nod to Eli Lilly.
In 1996, when Scott-Levin last surveyed health care professionals about corporations and respect, Merck was ranked first by physicians. Scott-Levin has surveyed physicians on their preferences biennially since 1992. PR
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
MDMA Therapy for Mental Health Conditions: Do the Benefits Outweigh the Risks?
October 25th 2024Despite a recent FDA Complete Response Letter issued to Lykos for midomafetamine capsules for the treatment of post-traumatic stress disorder, experts believe that the future is bright for psychedelic drugs that treat mental health conditions.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.